FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma
This trial is active, not recruiting.
|Condition||diffuse large b cell lymphoma|
|Treatments||autologous blood stem transplantation, r-chop (rituximab, cyclphosphamide, etoposide, cisplatin, mesna, g-csf|
|Sponsor||AHS Cancer Control Alberta|
|Start date||July 2007|
|End date||August 2011|
|Trial size||80 participants|
|Trial identifier||NCT00530179, 0307003|
The purpose of this study is to evaluate:
1. whether an imaging test called a PET (Positron emission tomography) scan performed after two cycles of standard chemotherapy is able to identify patients who have a high cure rate after completing standard chemotherapy alone; and
2. whether high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) when used in combination with an antibody called Rituximab results in high cure rates for those patients predicted to do poorly with standard chemotherapy by the PET scan.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Male or female participants from 18 years up to 65 years old.
Inclusion Criteria: - Age 18-65 years - Diagnosis of Diffuse Large B-Cell Lymphoma - Adverse Prognosis = Stage 3 or 4 and elevated LDH - No more than one prior cycle of R-CHOP chemotherapy - Adequate cardiac function - No central nervous system involvement by lymphoma Exclusion Criteria: - Histological diagnosis other than Diffuse Large B-cell Lymphoma - Pregnant or lactating females - Use of other anti-cancer therapies - Other serious illness that would compromise study participation - Prior malignancy - Prior stem cell transplant or radiotherapy
|Official title||FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma|
|Principal investigator||Douglas Stewart, M.D.|
Call for more information